Calcitonin screening in patients with thyroid nodules

C. Schneider; C. Kobe; M. Schmidt; D. Kahraman; G. Malchau; M. Faust; H. Schicha; M. Dietlein

doi:10.3413/Nukmed-0494-12-04

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2012; 51(06): 228-233
DOI: 10.3413/Nukmed-0494-12-04

Original article

Schattauer GmbH

Calcitonin screening in patients with thyroid nodules

Diagnostic valueCalcitonin-Screening bei Patienten mit Schild - drüsenknotenDiagnostische Bedeutung

C. Schneider

¹Department of Nuclear Medicine, University Hospital of Cologne

,

C. Kobe

¹Department of Nuclear Medicine, University Hospital of Cologne

,

M. Schmidt

¹Department of Nuclear Medicine, University Hospital of Cologne

,

D. Kahraman

¹Department of Nuclear Medicine, University Hospital of Cologne

,

G. Malchau

²Institute of Clinical Chemistry, University Hospital of Cologne

,

M. Faust

³Department of Endocrinology, Diabetes and Preventive Medicine, University Hospital of Cologne, Germany

,

H. Schicha

¹Department of Nuclear Medicine, University Hospital of Cologne

,

M. Dietlein

¹Department of Nuclear Medicine, University Hospital of Cologne

› Author Affiliations

Abstract

Summary

Aim: The positive predictive value (PPV) of a slightly elevated basal calcitonin (CT) for the diagnosis of medullary thyroid cancer (MTC) is still under debate. Patients, methods: A total of 11 270 patients with thyroid nodules underwent calcitonin screening. Patients with known elevation of CT, renal insufficiency, bacterial infection, alcohol abuse, protonpump inhibitor therapy or autoimmune thyroid disease were excluded from further analysis. Serum CT was determined by the solid-phase, enzyme-labeled, two-site chemiluminescent immunoassay Immulite 2000. If possible, a pentagastrin test was done to differentiate cases of hypercalcitoninaemia. Results: Hypercalcitoninsemia was found in 32 patients. 20 patients underwent surgery. In 10 patients a MTC was found. The PPV of hyper calcitoninaemia for MTC was 31%. The PPV increased to 50% for those patients who underwent surgery (10/20). A subgroup of 26 patients presented with basal CT between 13 and 50 pg/ml, 14 of them underwent surgery, in 4 cases evidence of MTC was revealed. This resulted in a PPV of 15% (4/26), although the value increased to 28% when only surgically treated patients were considered (4/14). Conclusion: Taking all clinical data into account, calcitonin screening has an acceptable PPV for medullary thyroid cancer in patients with thyroid nodules. Therefore, we recommend calcitonin screening in centers for thyroid disorders.

Zusammenfassung

Ziel: Der positive Vorhersagewert (PPV) eines leicht erhöhten basalen Calcitonin-Spiegels (bCT) für das Vorliegen eines medullären Schilddrüsenkarzinoms (MTC) wird kontrovers diskutiert. Patienten und Methodik: 11 270 Patienten mit Schilddrüsenknoten erhielten eine Bestimmung des Calcitonin-Spiegels. Ausgeschlossen wurden Patienten mit bekannter Erhöhung des Calcitonin-Werts, Niereninsuffizienz, bakterieller Entzündung, Alkoholabusus, Einnahme von Protonenpumpen-Inhibitoren oder einer Autoimmunerkrankung der Schilddrüse. Der Serumspiegel für Calcitonin wurde mittels Chemilumineszenz-Verfahren (Immulite 2000®) bestimmt. Im Fall einer Hypercalcitoninämie wurde – sofern verfügbar und möglich – ein Pentagastrin-Stimulationstest durchgeführt. Ergebnisse: Eine Hyper - calcitoninämie wurde für 32 Patienten dokumentiert. 20 Patienten wurden operiert. Bei 10 Patienten wurde ein MTC histologisch gesichert. Der PPV eines erhöhten Calcitonin- Spiegels für das Vorliegen eines MTC war 31 %. Der PPV der Hypercalcitoninämie erhöhte sich auf 50 %, wenn nur die operierten Patienten (10/20) betrachtet wurden. Eine Untergruppe von 26 Patienten wies ein leicht erhöhtes bCT zwischen 13 and 50 pg/ml auf, von denen 14 Patienten operiert und bei 4 Patienten ein MTC histologisch gesichert wurde. Der PPV eines leicht erhöhten bCT für das Vorliegen eines MTC (4/26) lag bei 15 %. Der PPV eines leicht erhöhten bCT erhöhte sich auf 28 %, wenn nur die operierten Patienten (4/14) betrachtet wurden. Schlussfolgerung: Wenn man alle klinischen Informationen berücksichtigt, weist das Calcitonin-Screening bei Patienten mit Schilddrüsenknoten einen akzeptablen PPV für das Vorliegen eines MTC auf. Daher empfehlen wir das Calcitonin- Screening in Schilddrüsenzentren.

Keywords

Calcitonin - screening - pentagastrin stimulation - thyroid nodule - medullary thyroid cancer

Schlüsselwörter

Calcitonin - Screening - Pentagastrin-Test - Schilddrüsenknoten - medulläres Schilddrüsenkarzinom

Full Text

References

References
1 Bieglmayer C, Scheuba C, Niederle B. et al. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr 2002; 114: 267-273.
2 Bieglmayer C, Vierhapper H, Dudczak R. et al. Measurement of calcitonin by immunoassay analyzers. Clin Chem Lab Med 2007; 45: 662-666.
3 Cavalier E, Carlisi A, Chapelle JP. et al. Analytic quality of calcitonin determination and its effect on the adequacy of screening for medullary carcinoma of the thyroid. Clin Chem 2008; 54: 929-930.
4 Cooper DS, Doherty GM, Haugen BR. et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
5 Costante G, Meringolo D, Durante C. et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 patients with thyroid nodules. J Clin Endocrinol Metabol 2007; 92: 450-455.
6 Dralle H, Machens A, Lorenz K. Hereditäre Schilddrüsenkarzinome. Chirurg 2008; 79: 1017-1028.
7 Elisei R. Routine serum calcitonin measurement in the evaluation of thyroid nodules. Best Pract Res Clin Endocrinol Metab 2008; 22: 941-953.
8 Elisei R, Bottici V, Luchetti F. et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10864 patients with nodular thyroid disorders. J Clin Endocrinol Metabol 2004; 89: 163-168.
9 Grauer A, Raue F, Ziegler R. et al. Clinical usefulness of a new chemiluminescent two-site immunoassay for human calcitonin. Exp Clin Endocrinol Diabetes 1998; 106: 289-291.
10 Görges R, Kandor T, Kuschnerus S. et al. Szintigraphisch mehranreichernde Schilddrüsenknoten gehen überwiegend mit normwertigem TSH einher. Nuklearmedizin 2011; 50: 179-188.
11 Hahm JR, Lee MS, Min YK. et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid 2001; 11: 73-80.
12 Hermann BL, Schmid KW, Goerges R. et al. Calcitonin screening and pentagastrin testing: predictive value for the diagnosis of medullary carcinoma in nodular thyroid disease. Eur J Endocrinol 2010; 162: 1141-1145.
13 Horvit PK, Gagel RF. The goitrous patient with an elevated serum calcitonin: what to do?. J Clin Endocrinol Metabol 1997; 82: 335-337.
14 Iacobone M, Niccoli-Sire P, Sebag F. et al. Can sporadic medullary thyroid carcinoma be biochemically predicted? Prospective analysis of 66 operated patients with elevated serum calcitonin levels. World J Surg 2002; 26: 886-890.
15 Karges W, Dralle H, Raue F. et al. Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter. German evidence-based consensus recommendation. Exp Clin Endocrinol Diabetes 2004; 112: 52-58.
16 Milone F, Ramundo V, Chiofalot MG. et al. Predicitve value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol 2010; 73: 85-88.
17 Nagarajah J, Sheu-Grabellus SY, Leitzen C. et al. Optimierung der Schilddrüsen-Feinnadelpunktion. Nuklearmedizin 2011; 50: 189-194.
18 Niccoli P, Wion-Barbot N, Caron Ph. et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomised patients. J Clin Endocrinol Metab 1997; 82: 338-341.
19 Pacini F, Schlumberger M, Dralle H. et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006; 154: 787-803.
20 Papi G, Corsello SM, Cioni K. et al. Value of routine measurement of serum calcitonin concentrations in patients with nodular thyroid disease: A multicenter study. J Endocrinol Invest 2006; 29: 427-437.
21 Papini E, Guglielmi R, Bianchini A. et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-doppler features. J Clin Endocrinol Metabol 2002; 87: 1941-1946.
22 Rieu M, Lame MC, Richard A. et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clin Endocrinol 1995; 42: 453-460.
23 Rink T, Truong PN, Schroth HJ. et al. Calculation and validation of a plasma calcitonin limit for early detection of medullary thyroid carcinoma in nodular thyroid disease. Thyroid 2009; 19: 327-332.
24 Scheuba C, Kaserer K, Moritz A. et al. Sporadic hypercalcitoninemia: clinical and therapeutic consequences. Endocr Relat Cancer 2009; 16: 243-253.
25 Schirpenbach C, Seiler L, Maser-Gluth C. et al. Automated chemiluminescence-immunoassay for aldosterone during dynamic testing: comparison to radioimmunoassays with and without extraction steps. Clin Chem 2006; 52: 1749-1755.
26 Vierhapper H, Niederle B, Bieglmayer C. et al. Early diagnosis and curative therapy of medullary thyroid carcinoma by routine measurement of serum calcitonin in patients with thyroid disorders. Thyroid 2005; 15: 1267-1272.
27 Vierhapper H, Raber W, Beiglmayer C. et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. J Clin Endocrinol Metab 1997; 82: 1589-1593.